Fortis Healthcare Ltd. Share Price

Overview

Fortis Healthcare Ltd. share price is currently ₹773.01, up by ₹19.28 (2.56%) from its previous closing price of ₹753.73. The share price has declined -14.31% over the past month and declined -18.76% over the past year. The stock's 52-week low and high are ₹732.69 and ₹1,094.60, respectively. Fortis Healthcare Ltd. has a market capitalisation of ₹ 63,250.00 Cr. The share price was last updated on 01 Oct 2026, 03:56 PM IST.

Fortis Healthcare Ltd.
Fortis Healthcare Ltd.
FORTIS
 ₹0.00
 ₹19.28
2.56%
Healthcare
 ₹0.00(%)1D

Updated: 01 Oct 2026, 03:56:06 pm IST

Market Data

Open Price

 ₹757.76

Prev. Close

 ₹753.73
 ₹732.69

Day Low

 ₹774.50

Day High

 ₹732.69

52 Week Low

 ₹1,094.60

52 Week High

HealthcareHospital & Healthcare Services
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

55.69

Sector PE

45.00

PB Ratio

5.90

Sector PB

5.98

EPS

13.88

Dividend Yield

0.13

Today's Volume

13.920 M

5 Day Avg. Volume

5.490 M

PEG Ratio

1.61

Market Cap.

₹ 63,250.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 10% at ₹1/Share
24-Jul-202624-Jul-2026
DividendsFinal Dividend of 10% at ₹1/Share
25-Jul-202525-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
HDFC Mid Cap Fund - Regular Plan - Growth3.24 Cr
3.21 Cr
(0.93%)
Kotak Mid Cap Fund - Regular Plan - Growth-
2.81 Cr
(100%)
Nippon India Growth Mid Cap Fund - Growth Option1.37 Cr
1.50 Cr
(9.9%)
Axis Midcap Fund - Regular Plan - Growth1.25 Cr
1.25 Cr
no change
DSP Midcap Fund - Regular Plan - Growth60.17 Lac
64.68 Lac
(7.49%)

About Fortis Healthcare Ltd. 👋

Fortis Healthcare Limited is an India-based integrated healthcare service provider. The Company is primarily engaged in the business of healthcare services. Its segment includes the Healthcare business and the Diagnostics business. The healthcare business includes inpatient and outpatient services, sale of medical and nonmedical items and management fees from hospitals. The diagnostic business includes pathology and radiology services. Its specialties include Cardiac sciences, Oncology, Neurosciences, Gastroenterology, Orthopedics, and others. The healthcare verticals of the Company primarily consist of day care specialty, diagnostics and tertiary and quaternary care. The Company has approximately 27 healthcare facilities in India, 4750 operational beds. It operates in India, United Arab Emirates, Nepal, and Sri Lanka.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Finkhoz Roboadvisory Services

Finkhoz Roboadvisory Services

1 Oct • 4:59 PM · SEBI-Registered Analyst

Apollo Hospitals extends fall as drug mark-up concerns

APOLLOHOSP
Enterprise Limited (APOLLOHOSP) fell 2.3% to ₹7,978 in early trade on October 1, extending losses for a second session. The stock was among the top Nifty 50 losers, a day after closing 6.6% lower on Supreme Court remarks about medicine mark-ups at private hospitals. The court cited a cancer drug with an MRP of ₹27,000 despite a price to retailers of ₹2,700. It questioned whether a uniform 16% margin could apply to medicines, and raised concerns about hospitals making patients buy through in-house pharmacies. The selling was sector-wide. Max Healthcare, Fortis Healthcare and KIMS were also down over 2% today. The concern is real, but its size is still unclear. Jefferies estimates medicines and consumables make up around 15-20% of hospital revenue. It puts the potential EBITDA impact at 2-5% under various price-cap scenarios, assuming hospitals cannot pass it on. The brokerage kept its positive view on the sector. HSBC also flagged pricing intervention as a key concern, while noting the ground-level impact remains uncertain. Most importantly, this is not yet a rule. The court's observations have not turned into a binding price-control order. The two-day fall reflects the market pricing in regulatory risk before any policy exists. Investors should watch for any government or regulatory action on hospital medicine pricing, the next court hearing, and management commentary in Q2 FY27 results. The key question is whether this ends as court observations or becomes a formal margin cap on hospital pharmacies. Disclosure: I do not hold any position in Apollo Hospitals Enterprise Limited. This post is for informational purposes only and is not investment advice.

See More
Kavan Patel

Kavan Patel

1 Oct • 3:32 PM · SEBI-Registered Analyst

Sensex, Bankex analysis for 01/10/2026(MARKET ANALYSIS)

1. Sensex Technical Overview Current Level: 72,480 Key Trend / Positioning: Hold Short (below 74,000): The current price of 72,480 sits comfortably below the major psychological and technical resistance threshold of 74,000. As long as Sensex trades below this boundary, the prevailing momentum favors downside continuation or a weak range-bound structure, supporting short positions. Conditional Long (above 74,000): A decisive breakout and sustained move above 74,000 would invalidate the short thesis, signaling a shift in market structure and a bullish trend reversal. Traders are advised to switch strategies to create long positions only upon confirmation of this breakout. 2. Bankex Technical Overview Current Level: 61,725 Key Trend / Positioning:Hold Short (below 63,000): Trading at 61,725, Bankex exhibits weakness as it remains capped under the key resistance barrier of 63,000. Holding short positions is favored in this zone, reflecting ongoing selling pressure or corrective momentum in banking constituents. Conditional Long (above 63,000): A reclaim of the 63,000 level would indicate aggressive institutional buying and a break of immediate overhead resistance. Long setups should only be initiated conditionally once the index successfully breaks and holds above this threshold. F&O top looser was :

FORTIS

See More
Pradeep Carpenter

Pradeep Carpenter

1 Oct • 6:39 AM · SEBI-Registered Analyst

Healthcare Stocks Fall: What Triggered the Sell-Off?

Indian healthcare stocks witnessed sharp selling on September 30, with major hospital names falling over 5%. Fortis Healthcare declined 6.33%, Apollo Hospitals Enterprise fell 5.70% and Max Healthcare Institute dropped 5.33%. The Nifty Healthcare Index also declined 2.57% to 16,137.75. The immediate trigger was the Supreme Court's scrutiny of medicine pricing at private hospitals. During a hearing on September 29, the court questioned the wide gap between the price paid by retailers and the MRP charged to patients. A cancer drug example highlighted a retailer price of around ₹2,700 versus an MRP of ₹27,000. The court also asked why a uniform 16% markup should not apply to medicines and medical devices. It raised concerns about patients being required to purchase medicines through hospital-linked pharmacies. However, this is not a final regulatory cap yet. The matter will be heard again on October 12. From an investor perspective, the concern is whether any future regulation could affect pharmacy-related margins and revenue streams of hospital companies. That uncertainty appears to have triggered broad-based selling rather than company-specific bad news. Technically, the Nifty Healthcare Index has weakened sharply, with RSI falling toward 37 and MACD momentum turning negative. However, the index remains above its major medium- and long-term moving averages. My sector view: The near-term outlook has turned cautious. I would watch the 16,000–15,600 zone closely. Sustaining this area could indicate that the current fall is a correction within the broader trend, while a decisive breakdown could increase selling pressure. On the upside, 16,500–16,800 remains an important recovery zone. Disclosure: I or my family members do not have any position in the stocks discussed above. This article is for educational purposes and not investment advice.

FORTIS

See More
Kavan Patel

Kavan Patel

1 Oct • 12:30 AM · SEBI-Registered Analyst

Nifty, Banknifty, Finnifty analysis for 01/10/2026

1. NiftyCurrent Level: 22,620 Trend Stance: Bearish / Short BiasKey Threshold: 23,100 Action Plan:Hold Short: Maintain short positions as long as Nifty trades below the 23,100 mark. Conditional Long: Switch to creating long positions only if the index decisively breaks and trades above 23,100. 2. Bank NiftyCurrent Level: 54,633 Trend Stance: Bearish / Short BiasKey Threshold: 55,400 Action Plan:Hold Short: Keep existing short positions active while trading below 55,400. Conditional Long: Consider entering long setups only on a breakout and sustained move above 55,400. 3. Fin NiftyCurrent Level: 24,649 Trend Stance: Bearish / Short BiasKey Threshold: 25,000 Action Plan:Hold Short: Maintain short positions below the psychological resistance level of 25,000. Conditional Long: Look to initiate long trades only if the index moves and sustains above 25,000. F&O top looser was :

FORTIS

See More
Hruthik N

Hruthik N

30 Sep • 11:13 PM · SEBI-Registered Analyst

Kotak Bank Leads as Healthcare Stocks Crash

The market closed lower today, with the Nifty50 down 95.75 points (0.42%) to 22,620.45, and the Sensex slipping 48.78 points (0.07%) to 72,480.29, a volatile session that pared early gains, extending the losing streak for a third straight day. FII outflows (₹10,148 crore net selling) and rising US bond yields added to the pressure. 1)

KOTAKBANK
was today's top gainer, rising 2.71% to close at ₹417.00, with banking broadly providing the market's main support. 2)InterGlobe Aviation (IndiGo) and ICICI Bank rounded out the top gainers, up 2.30% and 2.28% respectively, followed by UltraTech Cement (+1.17%) and Axis Bank (+1.15%), a clearly bank-and-cyclical-led list. 3)Healthcare stocks were hit hard on regulatory concerns. Apollo Hospitals fell 5.70%, dragging the Nifty50 the most, while Max Healthcare, Fortis, and Yatharth Hospital all slumped up to 7% on worries about a proposed price cap on private hospital room rents. 4)Sector performance was genuinely mixed, with 6 of 10 sector indices closing higher, Nifty Realty led with a 1.62% gain, while Nifty Pharma lagged, down 1.84%. Market breadth stayed weak, with only 17-18 of the Nifty50's 50 stocks advancing against 31-32 declining, so despite a few strong gainers, more stocks fell than rose. 5)Broader markets outpaced the Nifty, with midcaps up slightly and smallcaps gaining 0.27%, led by names like Cupid (+8.23%, near its 52-week high) and Aegis Logistics (+6.17%).

See More
Saurabh Tyagi--Clovek,Advisory

Saurabh Tyagi--Clovek,Advisory

30 Sep • 7:17 PM · SEBI-Registered Analyst

Hospital Stocks: Regulatory Risk Comes Into Focus

APOLLOHOSP
, Max Healthcare, Fortis Healthcare and other private hospital stocks came under selling pressure after the Supreme Court raised concerns over high mark-ups on medicines sold through corporate hospitals. The Court highlighted a case where a cancer drug with a price to retailer of around ₹2,700 carried an MRP of ₹27,000 and questioned whether a uniform 16% margin should apply to medicines and medical devices. The Court also questioned the practice of requiring patients to purchase medicines through in-house hospital pharmacies. The matter has been referred to the Centre for consideration, with the next hearing scheduled for October 12, 2026. Importantly, the 16% margin is currently an observation under consideration and is not a binding pricing regulation. For listed hospitals, the key concern is the potential impact on pharmacy-related revenue and margins if tighter pricing controls or restrictions on in-house pharmacy sales are eventually introduced. The actual financial impact will depend on the final regulatory framework and the extent of exposure of individual hospital chains. Investors should therefore monitor the government's response, the October 12 hearing and subsequent company disclosures.

See More

News & Events

Frequently Asked Questions

What is the share price of Fortis Healthcare Ltd.?

What is the market cap of Fortis Healthcare Ltd.?

Should I buy Fortis Healthcare Ltd. stock now?

What is the 52 week high and low of Fortis Healthcare Ltd.?

Is the Fortis Healthcare Ltd. stock good to buy?

Is Fortis Healthcare Ltd. a good buy for the long term?

Is Fortis Healthcare Ltd. overvalued or undervalued?

What is the PE and PB ratio of Fortis Healthcare Ltd.?

Start Now